

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

#### MTA: Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis [ID3834]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### Consultation

1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how?

During scoping consultation, the following point was raised:

- People without a F508 del mutation make up a higher-proportion of the non-white population with CF. By restricting this HTA to people with one or two F508del, there is a risk of discriminating against ethnic groups with lower frequency of this variant

This issue is discussed in section 3.25 of the draft guidance.

2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these?

No

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

No

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

No

7. Have the committee's considerations of equality issues been described in the draft guidance, and, if so, where?

Yes, see section 3.25 of the draft guidance

**Approved by Associate Director (name):** Jacoline Bouvy

**Date:** 26/10/2023

## Final draft guidance

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

Equality issues raised in response to consultation on the draft guidance included:

- Age:
  - a negative recommendation would have meant that people already old enough to have started treatment would continue treatment, but younger people who had not already started treatment would be left without access
- Disability:
  - a negative recommendation would have resulted in unequal access to treatments for children with the same disability
  - people with some neurological conditions (such as ADHD or autism spectrum disorder) and their carers, may find managing CF disproportionately difficult – modulator treatment has provided an additional important benefit for them that would have been lost if the final guidance was negative

As the final draft guidance recommendation is positive, these potential equality issues no longer apply.

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on

people with disabilities because of something that is a consequence of the disability?
No

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?
No

5. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?
Yes – see final draft guidance section 3.26.

**Approved by Associate Director (name):** ...Linda Landells.....

**Date:** May 2024